NCT00905138View on ClinicalTrials.gov

First-in-Human Single Ascending and Multiple Dose of GLPG0259

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Healthy

Interventions

DRUG

GLPG0259

single ascending doses, oral solution

DRUG

placebo

single dose, oral solution

DRUG

GLPG0259

multiple dose, oral solution, 5 days

DRUG

placebo

oral solution, 5 days

Trial Locations (1)

Unknown

SGS Stuivenberg, Antwerp

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Galapagos NV

INDUSTRY